



Pharmacy and Therapeutics Committee Meeting Agenda

Wednesday, January 15, 2025

7:30 – 9:30 am

To arrange for public building access, please contact
Sue Chan at 415-615-4461

San Francisco Health Plan
50 Beale St.
San Francisco, CA, 94105
City Hall Conference Room

- 1) Call to order – non-voting item (est. time 5 minutes)
Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan
 - Conflict of interest check
 - Attendance/Quorum
 - Agenda overview
- 2) Review and Approval of October 16, 2024, P&T minutes – voting item (est. time 3 minutes)
Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan
- 3) Informational Updates – non-voting item (est. time 10 minutes)
Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan
Brian Ellsworth, PharmD, Pharmacy Director, San Francisco Health Plan
Katrina (Katie) Vo, Pharm D, Clinical Pharmacist, San Francisco Health Plan
 - D-SNP: Part-D Star Measures
- 4) Review and Approval of Prior Authorization Criteria Interim Changes – **voting item** (est. time 4 minutes)
Katie Vo, PharmD, Clinical Pharmacist, San Francisco Health Plan
- 5) Review and Approval of Formulary Interim Changes – **voting item** (est. time 3 minutes)
Katie Vo, PharmD, Clinical Pharmacist, San Francisco Health Plan
- ADJOURN TO CLOSED SESSION**
Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan
- 6) Consent Calendar – **voting item** (est. time 5 minutes)
Jessica Shost, PharmD, Clinical Pharmacist, San Francisco Health Plan
Katie Vo, PharmD, Clinical Pharmacist, San Francisco Health Plan
 - Drug Utilization Review (DUR) Reports and/or Educational Items
 - Prime/Magellan Rx Retrospective DUR Quarterly Activities 3Q2024
 - Statin letter
 - Opioids Letter
 - Prime/Magellan Rx Quarterly Prospective DUR Report 3Q2024
- 7) Discussion and Recommendations for Changes to SFHP Formulary and Prior Authorization Criteria and Drug Utilization Review Reports for Select Drug Classes - **voting item** (est. time 55 mins)
Jessica Shost, PharmD, Clinical Pharmacist, San Francisco Health Plan
Katie Vo, PharmD, Clinical Pharmacist, San Francisco Health Plan
Tammie Chau, PharmD, Clinical Pharmacist, San Francisco Health Plan
 - Cardiology



Pharmacy and Therapeutics Committee Meeting

Agenda

- Pulmonary Hypertension Class Review
 - Tryvio™ (aprocitentan) Monograph
 - Dermatology
 - Atopic Dermatitis Class Review
 - Infectious Disease
 - Hepatitis B Class Review
 - Hepatitis B DUR Analysis
 - Obstetrics and Gynecology
 - Contraceptives Class Review
 - Hormone Replacement Therapy Class Review
 - Pulmonary
 - Pulmonary Fibrosis Class Review
 - Rheumatology
 - Biologic and Non-Biologic DMARDs Class Review
- 8) DUR Program Updates, Reports, and/or Educational Items – non-voting item (est. time 15 minutes)
Jessica Shost, PharmD, Clinical Pharmacist, San Francisco Health Plan
- Fraud, Waste and Abuse (FWA) DUR Report: Multiple Providers and Multiple Pharmacies Q2024
 - QI measures associated with DUR program
- RECONVENE IN OPEN SESSION**
Summary of Closed Session – non-voting item (est. time 5 minutes)
Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan
- 9) Annual Pharmacy Policies and Procedures (P&Ps) Review – **voting item** (est. time 5 minutes)
Sue Chan, Pharmacy Compliance Program Manager, San Francisco Health Plan
- Pharm-02 Pharmacy and Therapeutics Committee
- 10) Appendix: Prime Therapeutics Pipeline Report 3Q2024– non-voting item (est. time 5 minutes)
Ai Quynh Nguyen, PharmD, Pharmacist Account Manager, Prime Therapeutics
- 11) Adjournment
- Upcoming P&T Committee meeting dates
 - **Wednesday, April 16, 2025**
 - **Wednesday, July 16, 2025**
 - **Wednesday, October 15, 2025**
 - **Wednesday, January 21, 2026**